Evotec and Exscientia Initiate Human Clinical Trials of their Novel Immuno-Oncology Drug

 Evotec and Exscientia Initiate Human Clinical Trials of their Novel Immuno-Oncology Drug

Evotec and Exscientia Initiate Human Clinical Trials of their Novel Immuno-Oncology Drug

Shots:

  • The companies initiate the clinical trial of A2a receptor antagonist, co-developed by Exscientia and Evotec utilizing Exscientia’s AI-design platform, Centaur Chemist
  • Exscientia will lead the clinical development phase of the molecule and Evotec retains co-ownership rights throughout clinical development
  • The A2a receptor is currently in development for adult patients with advanced solid tumors and has the potential to show high selectivity for the targeted receptor

Click here to­ read full press release/ article | Ref: Evotec | Image: Wikipedia

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post